Does preirradiation PSA predict biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation?
Biochemical disease-free survival after postprostatectomy radiation is predicted by the PSA at the time of irradiation. Clinical local control is excellent, but distant failure remains a significant problem in this population. The addition of concomitant systemic therapy should be investigated in patients with PSA >2.7.
In patients without diabetes mellitus, markers of enhanced cholesterol absorption were a strong predictor for concomitant CVD.